With the rapid research and development of cellular therapy products, new stem cell-derived cellular therapy products are constantly being developed, but only few relevant guidance documents to assist the design of studies for non-clinical safety evaluation have been published. Stem cell-derived cellular therapy products not only come from different sources, but also have different safety factors and potential risks of ectopic tissue formation, uncontrolled biological distribution, immunogenicity and tumorigenicity, etc. Different stem cell-derived cellular therapy products bring great challenges to non-clinical studies. The paper gives a brief overview of the types of stem cells and general principles for the non-clinical safety evaluation of stem cell-derived cellular therapy products, focusing on the animal selection, experimental design and tumorigenicity study, in order to provide some references for non-clinical safety evaluation of stem cell-derived cellular therapy products in China.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |